Protagonist Therapeutics Inc (PTGX) — Capital Reinvestment Ratio

Latest as of March 2025: 0.00x

Protagonist Therapeutics Inc (PTGX) has a Capital Reinvestment Ratio of 0.00x as of March 2025, meaning it reinvests 0% of its operating cash flow ($125.36 Million) in capital expenditures ($545.00K). Check PTGX tangible net assets ratio to evaluate the tangible quality of the company's equity base.

Capital Reinvestment Ratio

0.00x
Capex / Operating Cash Flow

Operating Cash Flow

$125.36 Million
USD

Capital Expenditures

$545.00K
USD

Data as of

Mar 2025
Most recent filing

Protagonist Therapeutics Inc Capital Reinvestment Ratio (2017–2024)

This chart tracks Protagonist Therapeutics Inc's Capital Reinvestment Ratio across 2 annual periods. For the full cash flow conversion analysis, see Protagonist Therapeutics Inc cash flow conversion.

Annual Capital Reinvestment Ratio for Protagonist Therapeutics Inc (2017–2024)

Year-by-year Capital Reinvestment Ratio for Protagonist Therapeutics Inc from 2017 to 2024. See PTGX FCF generation index to measure how efficiently the company converts operating cash flow to free cash.

Year Reinvestment Ratio Operating CF (USD) Capital Expenditures YoY Change
2024 0.01x $184.15 Million $1.35 Million ▼ -95.7%
2017 0.17x $3.87 Million $666.00K
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow